Haemonetics (HAE) Receiving Somewhat Favorable Press Coverage, Study Shows

Media headlines about Haemonetics (NYSE:HAE) have been trending somewhat positive this week, AlphaOne Sentiment reports. The research firm, a service of Accern, rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics earned a media sentiment score of 0.11 on AlphaOne’s scale. AlphaOne also assigned media coverage about the medical instruments supplier an impact score of 68 out of 100, indicating that recent news coverage is likely to have an effect on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Alpha One Sentiment Analysis’s rankings:

Several research firms have issued reports on HAE. Zacks Investment Research upgraded Haemonetics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 7th. Barrington Research cut Haemonetics from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 7th. Finally, TheStreet upgraded Haemonetics from a “c” rating to a “b-” rating in a report on Thursday, April 13th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $34.57.

Haemonetics (NYSE:HAE) traded down 0.27% on Friday, hitting $40.73. 136,099 shares of the company’s stock traded hands. The stock has a market cap of $2.12 billion, a PE ratio of 129.71 and a beta of 0.92. Haemonetics has a one year low of $25.98 and a one year high of $41.65. The stock has a 50-day moving average of $39.76 and a 200-day moving average of $38.59.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Monday, February 6th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. The business had revenue of $227.80 million for the quarter, compared to the consensus estimate of $220 million. Haemonetics had a net margin of 1.79% and a return on equity of 10.51%. The business’s revenue was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.48 EPS. On average, equities analysts forecast that Haemonetics will post $1.52 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/04/21/haemonetics-hae-receives-news-impact-rating-of-0-11-updated.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply